Vitality Watch

Dossier pubmed observational 05-nov-2026
Human cohort, case-control, or epidemiological association

Rapamycin and human longevity among kidney transplant recipients surviving the first year.

Key claim: In a propensity-score-weighted cohort of over 11,000 kidney transplant recipients followed for a median of 11 years, chronic rapamycin exposure was not associated with an improvement in long-term survival.

Abstract

Rapamycin, an mTOR inhibitor, continues to be investigated for hypothesized physiological, disease prevention, and longevity benefits, but few studies have been conducted in humans. Using US national organ transplant registry data, one of the largest real-world datasets examining chronic rapamycin exposure in humans, we compared the Kaplan-Meier survival age distribution of 4885 kidney transplant recipients prescribed rapamycin compared to 6589 recipients not prescribed rapamycin. Recipients were followed a median of 11 years and 6443 died during the study period. Propensity score weighting was used to adjust for exposure group differences in age, BMI, diabetes, and 15 other factors. After adjusting for demographic and clinical differences between groups, the median survival age of 64.6 years in the rapamycin group and 64.3 years in the non-rapamycin group were statistically similar (95% confidence interval for median survival age difference -1.6, 2.0 years). In this large cohort of kidney transplant recipients who were alive with a functioning graft at 1 year post-transplant, we did not observe a meaningful improvement in long-term survival with mTOR inhibition.

Why this matters

[human-observational] This large, long-followed transplant cohort adds a human survival endpoint to the mTOR-inhibition evidence base without finding a survival advantage associated with chronic rapamycin exposure. It leaves the gap between model-organism longevity biology and human longevity claims unresolved: observational transplant-treatment data neither establish a causal lack of benefit nor determine effects in otherwise healthy people or with different dosing schedules.

Source

Link

Briefing card

Rapamycin and human longevity among kidney transplant recipients surviving the first year.
Stage: observational · pubmed · 05-nov-2026

If you are a kidney transplant recipient who survived the first post-transplant year, this observational cohort found no long-term survival advantage associated with chronic rapamycin exposure.

In a propensity-score-weighted cohort of over 11,000 kidney transplant recipients followed for a median of 11 years, chronic rapamycin exposure was not associated with an improvement in long-term survival.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11357-026-02643-8

build build 880 · 2bcef25 · 2026-11-18